Table 3. Baseline Characteristics.
| Total (n = 98) | TT (n = 48) | DT (n = 31) | DAPT (n = 19) | P-value | |
|---|---|---|---|---|---|
| Age(years) | 73 ± 7.5 | 72 ± 7.5 | 73 ± 8 | 77 ± 5 | 0.045 |
| Male gender | 44 (45%) | 22 (46%) | 12 (39%) | 10 (53%) | 0.62 |
| Hypertension | 76 (77.5%) | 36 (75%) | 27 (87%) | 13 (68%) | 0.257 |
| Diabetes | 34 (35%) | 18 (37.5%) | 10 (32%) | 6 (31.5%) | 0.848 |
| Hypercholesterolemia | 54 (55%) | 27 (56%) | 18 (57%) | 9 (47%) | 0.742 |
| Current smoking | 16 (16.5%) | 6 (12.5%) | 6 (19.3%) | 4 (21%) | 0.596 |
| Body mass index | 27.7 ± 2 | 27 ± 2 | 28 ± 2 | 29 ± 2 | 0.006 |
| Previous TIA/stroke | 13 (13.2%) | 10 (20.8%) | 2 (6.45%) | 1 (5.2%) | 0.095 |
| Previous AMI | 24 (24.5%) | 12 (25%) | 6 (19.3%) | 6 (31.5%) | 0.617 |
| Previous PCI-S/CABG | 34 (34.6%) | 17 (35%) | 10 (32%) | 7 (37%) | 0.936 |
| Previous major bleeding | 4 (4%) | 0 | 2 (6.45%) | 2 (10.5%) | 0.125 |
| Chronic heart failure | 15 (15.3%) | 12 (25%) | 3 (9.6%) | 0 | 0.022 |
| Chronic kidney disease | 28 (28.5%) | 13 (27%) | 8 (26%) | 7 (37%) | 0.668 |
| Anemia | 12 (11.2%) | 1 (2%) | 5 (16%) | 6 (31.5%) | 0.003 |
| LVEF | 50 ± 5 | 50.7 ± 4.7 | 49.8 ± 6 | 50 ± 5 | 0.738 |
| eGFR(MDRD) | 68 ± 15.6 | 72 ± 14 | 64 ± 14 | 66 ± 11.5 | 0.068 |
| AF | 90 (92%) | 48 (100%) | 23 (74%) | 19 (100%) | 0.0001 |
| Indication for prophylaxis of cardioembolism or venous thromboembolism | |||||
| AF | 74 (75.5%) | 32 (85.4%) | 28 (90%) | 14 (73.6%) | 0,056 |
| Previous VTE/cardiac embolism | 3 (3.06%) | 3 (6.25%) | 0 | 0 | 0.199 |
| Dilated cardiomyopathy without AF | 1 (1.02%) | 0 | 0 | 1 (5%) | 0.335 |
| Mechanical valve with or without AF | 20 (20.4%) | 13 (27%) | 3 (25.8%) | 4 (15.8%) | 0.172 |
| Indication for PCI -S requiring antiaggregant agents for a period of 1 month (BMS) or 9 - 12 months (DES) | |||||
| Stable exertional angina | 30 (30.6%) | 12 (25%) | 12 (38.7%) | 6 (31.6%) | 0.432 |
| NSTE-ACS | 49 (50%) | 23 (48%) | 13 (42%) | 13 (68.4%) | 0.176 |
| Acute STEMI | 19 (19.3%) | 13 (21%) | 6 (19.3%) | 0 | 0.043 |
Data are reported as absolute number (percentage) or mean ± standard deviation. TT: triple therapy (warfarin + acetylsalicylic acid and clopidogrel); DT: dual therapy (warfarin + acetylsalicylic acid or clopidogrel); DAPT: dual antiplatelet therapy (acetylsalicylic acid + clopidogrel); TIA: transient ischemic attack; AMI: acute myocardial infarction; PCI-S: percutaneous coronary intervention with stent; CABG: coronary artery bypass graft; LVEF: left ventricular ejection fraction; eGFR: estimated glomerular filtration rate; MDRD: Modification of Diet in Renal Disease Study equation; AF: atrial fibrillation; VTE: venous thromboembolism; BMS: bare metal stent; DES: drug-eluting stent; NSTE-ACS: non-ST elevation acute coronary syndrome; STEMI: ST-elevation myocardial infarction.